Posted by Michael Wonder on 27 Jun 2024
Vir Biotechnology receives FDA fast track designation for tobevibart and elebsiran for the treatment of chronic hepatitis delta infection
26 June 2024 - Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta.
Vir Biotechnology today announced that the US FDA has cleared its investigational new drug application and granted fast track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection.
